Filana Therapeutics (MEX:FLNA) Research & Development: MXN320.20 Mil (TTM As of Mar. 2026)


MEX:FLNA Filana Therapeutics Inc MEX:FLNA
33 GF Score
Price MXN27.00
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Research & Development?

Filana Therapeutics MEX:FLNA 33 Research & Development is MXN320.20 Mil as of Mar. 2026. GuruFocus rates MEX:FLNA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Filana Therapeutics's Research & Development for the three months ended in Mar. 2026 was MXN81.94 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN320.20 Mil.

Filana Therapeutics  (MEX:FLNA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Filana Therapeutics Research & Development Related Terms

Filana Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics Research & Development Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 509.01 1,326.35 1,517.89 1,452.33 478.77

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 279.58 96.33 72.55 69.38 81.94
MEX:FLNA
33GF Score
Filana Therapeutics Inc MEX:FLNA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN320.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN320.20 Mil mean?
Filana Therapeutics (MEX:FLNA) has a Research & Development of MXN320.20 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Filana Therapeutics and its competitors.
Is Filana Therapeutics' Research & Development too high?
Filana Therapeutics' current Research & Development is MXN320.20 Mil. Overall, Filana Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' Research & Development compare to XBIT and MCRB?
Filana Therapeutics' Research & Development of MXN320.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Filana Therapeutics and its competitors. Filana Therapeutics's current Research & Development is MXN320.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (MEX:FLNA) has a current Research & Development of MXN320.20 Mil. The current Research & Development is MXN320.20 Mil. Filana Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Filana Therapeutics (MEX:FLNA), the current Research & Development is MXN320.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Other Exchanges FLNA:USAPX91:Germany
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
33GF Score

Get the complete analysis for MEX:FLNA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN27.00
Price